App Logo
menu

Menu

close
expand_more

Myeloma Resources

expand_less
/
/
Helpful Resources for Multiple Myeloma Patients Considering Stem Cell Transplants
Helpful Resources for Multiple Myeloma Patients Considering Stem Cell Transplants
Posted Apr 06, 2021

I clearly remember the early days of my own treatment (7 years ago) for a high-risk myeloma variant. There weren’t enough hours in the day to not just compile the list of questions but to also find the answers. Sure, there were some resources available but not to the same extent as we have now, especially with the Myeloma Crowd by HealthTree and HealthTree University (Stem Cell Transplant is in Course 8). Many of those questions dealt with stem cell transplants (SCT), and I would expect that many recently diagnosed patients will also have a similar wealth of questions.

The Journal Cancers recently dedicated a special issue solely to Stem Cell Transplants in Cancer Treatment with, probably, the best survey article, titled “Role of Stem Cell Transplantation in Multiple Myeloma”, that I have seen in my years of reading journals. Even though the article was published in a medical journal it is remarkably easy to read and chances are that you will learn much of immediate potential use but also to gain a good grasp of things that are on the horizon with respect to myeloma treatment. I will not even try to summarize this article, as there is so much to digest, but just whet your appetite by listing the key topics you will find answers to:

  • Some history about SCT (always nice to know)
  • Patient eligibility in SCT for multiple myeloma
    • Patient related factors
    • Renal (kidney) insufficiency and auto SCT
    • Induction therapy 
    • Conditioning therapy
    • The role of SCT as conditioning therapy
    • Single or tandem (back-to-back) SCT 
    • Timing of auto-SCT
    • Auto-SCT as salvage therapy
    • The role of maintenance treatment after SCT
    • Allogeneic (donor) SCT
    • The role of Minimal Residual Disease (MRD) in SCT
    • There is some nice discussion in the ‘Conclusions’ section of the article about novel methods of treatment (such a CAR-T, bi-specific antibodies, different immune targets, Natural Killer (NK) cells, and others) that we will be seeing in clinical practice as time goes on.

This article is highly recommended, not just for the recently diagnosed/’new’ patients but also for those of us who already went through the SCT process, as you are bound to learn something new, here and there, that may become of value to you sometime in the future.

Additionally, consider joining our new Stem Cell Transplant Chapter to hear important topics about stem cell transplant and chat with others who have gone through the experience. Join this new chapter today! 

<a href="https://healthtree.org/aml/community">Find more myeloma news and information on www.myelomacrowd.org</a>

More Myeloma 101 Articles

Article Image Thank Your Myeloma Doctor on National Doctor Day During Myeloma Awareness Month Article Image FDA Grants First anti-BCMA CAR T Approval in Multiple Myeloma for Abecma Article Image BCMA and Other Targets: Register Now for the Myeloma Crowd Round Table Webcast on April 10

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Follow Us

facebook instagram twitter youtube

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811